Novacyt, together with Queen Mary University of London, began clinical trials using an innovative stationary testing system. The aim of the study is to find out whether daily COVID-19 testing reduces the frequency of infection, morbidity and mortality among high-risk populations. The study will involve 2000 people in 50 nursing homes in London.